Peginterferon-α-2a/ribavirin
1
Reactions 1506, p22 - 21 Jun 2014 S Peginterferon-α-2a/ribavirin Anaemia and worsening of obsessive-compulsive disorder: case report A 25-year-old man developed anaemia and worsening of his obsessive-comulsive disorder during treatment with peginterferon-α-2a and ribavirin. In April 2010, the man had been hospitalised with a recently discovered hepatitis C virus (HCV) infection. He also had obsessive-compulsive disorder and Charcot Marie Tooth disease. He started treatment with SC peginterferon-α-2a 180mg once weekly and oral ribavirin 1400mg/day. Treatment was mildly tolerated, apart from a mild worsening of his psychiatric symptoms, requiring admission to a protected structure with no pharmacological treatment, and an important anaemia [duration of treatment to reaction onsets and outcomes not stated]. His haemoglobin level decreased by >5 g/dL, with a nadir of 8.8 g/dL. He achieved a negative viral load 2 weeks after starting treatment, and was treated for a total of 12 weeks. Author comment: "Antiviral therapy of chronic hepatitis C with Peg-IFNα is associated with several neuropsychiatric side effects." "The worsening of our patient’s psychiatric symptoms, during anti-HCV therapy, was probably due to Peg-IFN (he had taken his psychiatric therapy for may years without side effects), and a careful monitoring of his condition was necessary to successfully complete a full course of antiviral treatment." Guardigni V, et al. Successful antiviral treatment of chronic Hepatitis C in patients with rare comorbidities. Two case-reports. Annals of Hepatology 11: 404-408, No. 3, Jan 2012 - Italy 803104850 1 Reactions 21 Jun 2014 No. 1506 0114-9954/14/1506-0001/$14.95 Adis © 2014 Springer International Publishing AG. All rights reserved
Transcript of Peginterferon-α-2a/ribavirin
Reactions 1506, p22 - 21 Jun 2014
SPeginterferon-α-2a/ribavirin
Anaemia and worsening of obsessive-compulsivedisorder: case report
A 25-year-old man developed anaemia and worsening of hisobsessive-comulsive disorder during treatment withpeginterferon-α-2a and ribavirin.
In April 2010, the man had been hospitalised with a recentlydiscovered hepatitis C virus (HCV) infection. He also hadobsessive-compulsive disorder and Charcot Marie Toothdisease. He started treatment with SC peginterferon-α-2a180mg once weekly and oral ribavirin 1400mg/day. Treatmentwas mildly tolerated, apart from a mild worsening of hispsychiatric symptoms, requiring admission to a protectedstructure with no pharmacological treatment, and animportant anaemia [duration of treatment to reaction onsetsand outcomes not stated]. His haemoglobin level decreased by>5 g/dL, with a nadir of 8.8 g/dL. He achieved a negative viralload 2 weeks after starting treatment, and was treated for atotal of 12 weeks.
Author comment: "Antiviral therapy of chronic hepatitis Cwith Peg-IFNα is associated with several neuropsychiatric sideeffects." "The worsening of our patient’s psychiatricsymptoms, during anti-HCV therapy, was probably due toPeg-IFN (he had taken his psychiatric therapy for may yearswithout side effects), and a careful monitoring of hiscondition was necessary to successfully complete a full courseof antiviral treatment."Guardigni V, et al. Successful antiviral treatment of chronic Hepatitis C in patientswith rare comorbidities. Two case-reports. Annals of Hepatology 11: 404-408, No.3, Jan 2012 - Italy 803104850
1
Reactions 21 Jun 2014 No. 15060114-9954/14/1506-0001/$14.95 Adis © 2014 Springer International Publishing AG. All rights reserved
